Improving Treatment-Related Symptom Management in Adolescents and Young Adults With Cancer

Not Applicable

Completed

• Conditions: Cancer

• Registration Number: NCT04594096
• Lead Sponsor: University of California, Davis

Brief Summary

This study will test the acceptability and feasibility of a telehealth intervention to improve communication between patients and medical providers in adolescent and young adult (AYA) cancer patients receiving chemotherapy treatment.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2020-10-14
• Study First Submitted QC: 2020-10-19
• Study First Posted: 2020-10-20
• Study Start: 2021-09-30
• Primary Completion: 2023-12-31
• Study Completion: 2023-12-31
• Status Verified: 2024-05
• Last Update Submitted: 2024-05-07
• Last Update Posted: 2024-05-09

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

• Patients with cancer undergoing active treatment and who have received at least two cycles of chemotherapy
• Access to Epic MyChart (we will facilitate access to MyChart for interested patients who are not yet signed up)
• Access to a smartphone or tablet to access EPIC MyChart telehealth appointments

Exclusion Criteria

• Non-English or non-Spanish speaking patients
• Potentially completing therapy during study period (including follow-up period) or plans to leave UCDCCC during study period

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Primary Outcome Measures

Name	Time	Method
Proportion of Patients Completing the Trial	end of the study period (6 cycles of chemotherapy for each participant, where each cycle is 14-28 days)	\>65% of enrolled patients will complete the trial

Secondary Outcome Measures

Name	Time	Method
Survey Response Rate	end of the study period (6 cycles of chemotherapy for each participant, where each cycle is 14-28 days)	\>%70% of enrolled patients will complete the survey instruments
Telemedicine Satisfaction and Usefulness Questionnaire (TSUQ)	end of the study period (6 cycles of chemotherapy for each participant, where each cycle is 14-28 days)	A composite score of ≥40 (based on 10 items with a Likert scale of 1-5 strongly disagree to strongly agree)

Trial Locations

Locations (1)

Comprehensive Cancer Center; 🇺🇸 Sacramento, California, United States